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This study provide an up-to-date overview of the epidemiology and risk factors
for Candida bloodstream infection in Scotland in 2012/2013, and the antifungal
susceptibility of isolates from blood cultures from 11 National Health Service boards
within Scotland. Candida isolates were identified by chromogenic agar and confirmed
by MALDI–TOF methods. Survival and associated risk factors for patients stratified
as albicans and non-albicans cases were assessed. Information on the spectrum of
antifungals used was collected and summarized. The isolates sensitivity to different
antifungals was tested by broth microdilution method and interpreted according to
CLSI/EUCAST guidelines. Forty one percent of candidaemia cases were associated with
Candida albicans, followed by C. glabrata (35%), C. parapsilosis (11.5%), and remainder
with other Candida spp. C. albicans and C. glabrata infections were associated
with 20.9 and 16.3% mortality, respectively. Survival of patients with C. albicans
was significantly lower compared to non-C. albicans and catheter line removal in
C. albicans patients significantly increases the survival days. Predisposing factors
such as total parenteral nutrition, and number of days on mechanical ventilation or in
intensive care, were significantly associated with C. albicans infections. Fluconazole
was used extensively (64.5%) for treating candidaemia cases followed by echinocandins
(33.8%). Based on CLSI breakpoints, MIC test found no resistance to any antifungals
tested except 5.26% fluconazole resistance among C. glabrata isolates. Moreover,
by comparing to EUCAST breakpoints we found 3.95% of C. glabrata isolates were
resistant to anidulafungin. We have observed a shift in Candida spp. with an increasing
isolation of C. glabrata. Delay and choice of antifungal treatment are associated with
poor clinical outcomes.
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INTRODUCTION
Candida species remain a significant cause of nosocomial
bloodstream infections (BSIs), associated with prolonged hospital
stay in the ICU and high healthcare cost (Rentz et al.,
1998; Gudlaugsson et al., 2003). The global prevalence of
candidemia was reported to be highly variable among different
countries ranging between 1.1 and 14.4 cases per 105 population
(Odds et al., 2007; Arendrup, 2010; Gamaletsou et al., 2013;
Quindos, 2014; Cleveland et al., 2015; Osmanov and Denning,
2015). The maximum of 14.4 cases per 105 population
was reported in USA (Cleveland et al., 2015), though in
Scotland was recently reported to be 4.8 (Odds et al.,
2007).
Reports in recent years have established various risk factors
for Candida BSIs. The risk factors including broad-spectrum
antibiotics, parenteral nutrition, immuno-suppression due to
chemotherapy and radiotherapy, disruption of mucosal barriers
due to surgery, ICU admission and indwelling medical devices
such as central venous catheters (CVCs), are among the most
important predisposing factors for Candida BSI (Dimopoulos
et al., 2008; Leroy et al., 2009). Indeed, biofilm formation
by Candida spp. and choice of antifungal has been shown to
be risk factors for morbidity and mortality in candidaemia
cases (Tumbarello et al., 2007, 2012; Rajendran et al., 2015).
Though Candida albicans is the most prevalent, pathogenic
and robust biofilm former of the Candida species, there
are recent studies reporting non-C. albicans species (NCAS)
as frequent causes of candidemia (Nguyen et al., 1996;
Dimopoulos et al., 2008; Hachem et al., 2008). Prior patient
exposure to antifungals, particularly to azoles, appears to be
a predictor for NCAS associated candidaemia (Nguyen et al.,
1996).
Catheters are commonly used in ICU patients (∼90%),
and represent an easy entry route for Candida spp (Almirante
et al., 2005). Biofilm formation by Candida spp. including
C. albicans in indwelling lines is considerably difficult to
treat with antifungals due to their intrinsic drug resistance
(Ramage et al., 2012). Appropriate antifungal medication
and catheter removal are critical in preventing patient
mortality with line infections (Mermel et al., 2009; Cornely
et al., 2012; Koehler et al., 2014). Delaying antifungal
therapy appears to be a common practice, and the impact
on mortality may be significant with catheter related
infections. Fluconazole is a mainstay of treatment for candida
BSI, however, they are not effective against C. glabrata
or preformed biofilms (Lee et al., 2009; Ramage et al.,
2012; Castanheira et al., 2016; Goncalves et al., 2016). In
appropriate antifungal usage was reported to be associated
with high morbidity and excess hospital cost (Zilberberg et al.,
2010).
National epidemiological surveillance and antifungal
sensitivity testing of Candida BSIs is vital to stratify high-risk
patients and to identify the pattern of causative Candida
spp., which will in turn formulate guidelines for management
of candidaemia. Therefore the purpose of this study was to
investigate this in Scotland.
MATERIALS AND METHODS
Patients and Variables
A prospective study of all cases of candidaemia was carried
out within Scotland under NHS Caldicott Guardian approval
from March 2012 to February 2013. This work formed an
audit and as such ethics approval and patient consent are not
required in the NHS. This was mandated for the NHS by Health
Service Circular: HSC 1999/012. Candida BSI was reported in
217 patients from 11 different health boards; clinical data was
obtained from 150 patients. The complete data sets of patient
demographics, ICU admissions, underlying medical conditions,
information on immunosuppression, and details of antifungal
therapy were collected through a review of the medical case notes
from 8 health boards. Where available, patient outcomes were
followed prospectively for 30 days or until death from first blood
culture positive, and clinical details including the presence of
indwelling medical devices in the 30 days prior to the occurrence
of candidemia were also collected.
Isolates and Antifungal Testing
Blood cultures were performed according to routine standard
operating procedures in each of the referring laboratories. All
clinical isolates were obtained at the beginning of episode 1 and
independently identified using ColorexCandida chromogenic
plates (E&O Laboratories Ltd, Bonnybridge, UK) and were
stored in Microbank R© vials (Pro-Lab Diagnostics, Cheshire,
UK) at −80◦C until further use. Isolates identification were
further confirmed from sub-culture on glucose-peptone plates by
MALDI-TOF MS analysis using a Bruker Microflex to produce
the spectra which were then analyzed using the Bruker database.
MIC test for different antifungals were performed centrally
at Mycology Reference Laboratory, Public Health England,
Bristol, according to standard Clinical and Laboratory Standards
Institute (CLSI) broth microdilution methodology (CLSI, 2008).
Interpretive criteria used for fluconazole (FLZ), voriconazole
(VRZ), and anidulafungin (ANID) were performed in accordance
with the current CLSI guidelines (CLSI, 2012).
Statistical Analysis
Initially, all data were numerically coded and labeled for each
variable, which was analyzed using SPSS software (SPSS Inc.,
Chicago, IL, USA). Categorical variables were compared between
groups using the two-tailed χ2 test or Fisher’s exact test, as
appropriate. Two groups of any continuous variables were
compared using Student’s t-test or Mann–Whitney U-test as
appropriate. Variables showing a significant association with
survival found by Student’s t test or χ2 test (Supplementary Table
S2) were included into subsequent multivariate Cox’s regression
analysis, to generate the survival curves.
RESULTS AND DISCUSSION
We undertook a retrospective analysis of candidaemia patients in
Scotland as means of understanding the national epidemiology of
Candida species, associated risk factors and isolates sensitivity to
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TABLE 1 | Antifungals used.
Fluconazole Caspofungin Anidulafungin Micafungin Ambisome Voriconazole Other
Episode∗ 1
No. (%) 78 (64.5) 17 (14) 16 (13.2) 8 (6.6) 1 (0.8) 1 (0.8) 0 (0)
Patient ages (mean) 60.3 67.6 61.3 72.9 0.01 40 0 (0)
Route PO/IV IV IV IV IV IV
No. days used (mean) 6.5 4.7 8.9 4.8 8 1 0(0)
Outcome dead (no. (%)) 20 (27.4) 7 (43.75) 8 (57.1) 2 (33.3) 1 (100) 0 (0) 0 (0)
Species specific
[No. (%)]
Candida albicans 29 (59.2) 10 (20.4) 7 (14.3) 2 (4.1) 1 (2) 0 (0) 0 (0)
C. glabrata 27 (69.2) 2 (5.1) 5 (12.8) 4 (10.3) 0 (0) 1 (2.6) 0 (0)
C. parapsilosis 11 (55) 4 (20) 3 (15) 2 (10) 0 (0) 0 (0) 0 (0)
C. tropicalis 5 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Others 6 (75) 1 (12.5) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
Episode 2
No. (%) 40 (57.1) 4 (5.7) 16 (22.9) 1 (1.4) 2 (2.9) 1 (1.4) 6 (8.6)
No. days used (mean) 9.7 8.3 8.5 19 16 22 7.7
Episode 3
No. (%) 13 (50) 1 (3.8) 1 (3.8) 1 (3.8) 2 (7.7) 7 (26.9) 1 (3.8)
No. days used (mean) 7.8 19 10.83 2
∗An episode is defined as a positive blood culture >21 days after the last positive culture or if a new Candida sp. isolated.
FIGURE 1 | Association between patient mortality and the timing of
antifungal treatment. The timing of antifungal therapy was determined to be
before (BPS) or from the time when the first blood sample for different
Candida culture positive was collected to the time when antifungal treatment
was first administered to the patient. Number above each bar represents the
overall % mortality over different antifungal timings and the black portion
represent mortality associated with Candida albicans and white portion for
NCAS infections.
antifungal agents. Data from the most recent 2011 census list the
population of Scotland at 5,295,4031. Therefore the population-
based incidence of candidaemia in Scotland was calculated as
4.1 per 100,000 population for the year 2012/13. This data
is comparable to those of 2005/06 (4.8 cases per 100,000 of
population per year) (Odds et al., 2007). The minor discrepancy
between these two studies could be explained by a growing
1http://www.scrol.gov.uk/population-households
FIGURE 2 | Survival analysis for candidaemia patients. Patients with
bloodstream infections (BSIs) were grouped by C. albicans (n = 52) or non-C.
albicans (NCAS) spp. (n = 72) and censored at death, or day 30.
Cox-regression plots adjusted for patient age is shown. Comparison between
these curves found a statistically significant difference in mortality rate
(p < 0.05).
population and from reporting of the false positive cases, and is
therefore likely to represent a minimum estimate of the incidence
of candidaemia in Scotland. There were approximately equal
numbers of male and female patients with candidaemia and
at a mean age of 63 years (standard deviation ± 20.3 years).
During the study period, 33 out of 141 candidemia patients were
admitted to the ICU (23.4%).
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TABLE 2 | Comparison of risk factors for C. albicans and NCAS infections.
Variables % (No. patients) p
C. albicans NCAS∗
Mean ages 61.8 (60) 63.8 (90) 0.548
Male sex 27 (60) 50 (90) 0.136
Diabetes 19 (59) 29 (90) 0.572
Surgery in 1 month∗∗ 29 (56) 41 (85) 0.405
Radiotherapy 2 (13) 9 (22) 0.115
Chemotherapy 7 (13) 11 (23) 0.500
Solid organ transplant 2 (60) 3 (89) 0.680
Metastatic 12 (14) 13 (24) 0.077
Solid Tumor 17 (59) 36 (88) 0.093
Abdominal surgery 22 (27) 26 (31) 0.541
Autoimmune or genetic
disorder
4(60) 9 (89) 0.338
Renal failure 20 (52) 30 (77) 0.552
Liver disease 5 (52) 9 (82) 0.522
ICU admission 15 (54) 18 (79) 0.325
No of days on
ventilation∗∗ (mean)
7.08 (13) 2.18(11) 0.035
No of days on ICU∗∗
(mean)
7.87 (15) 4.12 (17) 0.045
Line in situ 53 (54) 76 (80) 0.328
Total parenteral nutrition 27 (51) 27 (78) 0.030
Antibiotics in 2 weeks ∗∗ 49 (52) 69 (78) 0.213
Antifungals in 3 months ∗∗ 9 (38) 17 (77) 0.417
Steroid in 3 months ∗∗ 16 (56) 17 (82) 0.195
∗NCAS, Non-Candida albicans species. ∗∗, prior to blood culture. Boldface
indicates a significant result.
Prevalence and Mortality Associated
with Candida spp
The prevalence of the different Candida species isolated from
the BS of candidaemia patients was assessed. Out of the 280
isolates collected in this study C. albicans predominated (41%),
followed byC. glabrata (35%),C. parapsilosis (11.5%),C. tropicalis
(3.6%), C. lusitaniae (3.6%), and other species (5.3%). Our
previous Scottish candidaemia study (2005/06)(Odds et al.,
2007) reported a prevalence of C. albicans and C. glabrata
as 50 and 21%, respectively (Supplementary Table S1). This
shows a changing trend in the prevalence of Candida spp
in causing BSI, with a considerable decrease of C. albicans
by 9% followed by a reciprocal increase of C. glabrata by
14%. C. parapsilosis did not show any clear change (∼12%
in both studies). These fluctuations are in accordance with
the global epidemiological changes, where in Denmark it has
been shown that the overall prevalence of C. albicans has
declined by 5% co-incidentally with an increase in C. glabrata
by 6.9% (year 2010–2011 compared to 2004–2009) (Eggimann
et al., 2011; Arendrup et al., 2013b). The reason for this is
unclear; however, studies suggesting an increase in the use of
FLZ have an impact on selection of C. glabrata (Pfaller and
Diekema, 2007; Arendrup et al., 2013b). Of the 129 cases where
patient mortality data was available, overall mortality was 41%
(n = 53), which was primarily associated with C. albicans
(49% [n = 26]), followed by C. glabrata (32% [n = 17]),
C. parapsilosis (11.3% [n = 6]), and other species (7.7%
[n= 4]).
Therapy
Fluconazole therapy was the predominant antifungal treatment,
out of 121 patients for which there was available antifungal
usage data. We define the episode as a positive blood culture
>21 days after the last positive culture or if a new Candida
spp. isolated. In this study we have reported maximum three
episodes from the isolate collection date up to 30 days time
period unless they discharged early or died. In episode 1, 78
were treated with FLZ (64.5%), 17 with CAS (14%), 16 with
ANID (13.2%), 8 with micafungin (6.6%), 1 with AmBisome
(0.8%), and 1 with VRZ (1%) (Table 1). In episode 2 there was
a 7.4% reduction in the use of FLZ, 8.3% reduction with CAS,
5.2% reduction with micafungin and 9.7% increase in the use
of ANID compared to previous episode (Table 1). Out of 78
FLZ treated patients in episode 1 20 (25.6%) were switched to
echinocandins in episode 2, due to resistance, line infection, no
improvement or microbiological advice. Patients with C. glabrata
showed the greatest treatment changes 37% (n = 10), though
50% (n = 5) of these patients’ clinical outcome was unsuccessful
(dead). For C. albicans 20.7% (n = 6) of the patients’ treatment
was changed, and only one was not successful. A previous study
reported an association of inappropriate initial therapy such
as FLZ to treat C. glabrata, which resulted in an increased
length of hospital stay and excess hospital cost (Zilberberg et al.,
2010). In addition, appropriate selection of initial antifungals
by empirical use of echinocandins was reported to be even
more cost effective than the use of FLZ (Zilberberg et al.,
2009).
Around 70% of candidemia patients do not receive empirical
antifungal therapy within 24 h of the time the blood sample
is drawn for culture. Previous studies have established the
negative impact of delayed antifungal treatment on the clinical
outcome of candidaemia cases (Morrell et al., 2005; Garey
et al., 2006; Kollef et al., 2012). In our study, we found 9
(8.3%) patients received antifungal treatment before a positive
sample (BPS) was collected, 21 (19.4%) patients received
treatment between 0 and 24 h, and 78 (72%) patients
after 24 h from the time at first positive blood sample
for culture was drawn. The relationship between hospital
mortality and the timing of the administration of antifungal
treatment is shown in Figure 1. Patients receiving antifungal
treatment BPS was drawn had a lower percentage mortality
than patients begun on antifungal treatment between 1–
24 h or >24 h (11% versus 19 or 33.1%). This is in
line with a previous study that reported an association of
delayed treatment by >12 h with increased hospital mortality
(p < 0.05) (Morrell et al., 2005; Kollef et al., 2012). Of the
patients with a BSI, we stratified groups according to the
presence of C. albicans or NCAS, as previously described
(Tumbarello et al., 2007; Dimopoulos et al., 2008). The data
shows that delayed treatment has a considerable impact on
NCAS associated mortality compared to C. albicans. Limitations
of the present study include differences in clinical practice
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FIGURE 3 | Days in the intensive care unit (ICU) or days in the ventilation before the extended prevalence of C. albicans, C. glabrata or other Candida
spp. infection. Values in bracket indicate number of patients included in each group. ∗C. albicans vs NCAS (p < 0.05).
FIGURE 4 | Survival analysis for candidaemia patients with and without line removal. Cox-regression plots adjusted for patient age is shown (A) Patients
with C. albicans infection (n = 24); p < 0.05, (B) patients with non-C. albicans infections (NCAS [n = 37]). p > 0.05 for C. albicans vs NCAS.
patterns across the different ward and different health boards,
incomplete data sets and as well as information on antifungal
dosing practices. Evading delays in treatment of candidemia
patients is challenging due to use of culture based diagnosis
methods.
Comparison of C. albicans with NCAS
Associated Candidaemia
The proportion of C. albicans and NCAS associated infections
was considerable among candidaemia cases from different health
boards, i.e., Ayrshire and Arran ([n = 22] 50 and 50%), Fife
([n = 11] 27.3 and 72.7%), Forth valley ([n = 11] 27.3 and
72.7%), Grampian ([n = 14] 50 and 50%), Greater Glasgow
and Clyde ([n = 39] 38.5 and 61.5), Lanarkshire ([n = 9]
33.3 and 66.7%), Lothian ([n = 26] 42.3 and 57.7%), and
Tayside ([n = 18] 38.9 and 61.1%). Overall, survival analysis
found a significantly higher mortality with patients infected with
C. albicans compared to NCAS (p < 0.05) (Figure 2). Though
previous studies from US, Greece and Taiwan, compared the
crude mortality of C. albicans with NCAS and showed mixed
results, here we showed a significant differences between these
spp. in patient survival curve analysis (Dimopoulos et al., 2008;
Moran et al., 2009; Chi et al., 2011). The various risk factors were
analyzed to find its influence on causing BSI by either C. albicans
or NCAS (Table 2). Patient demographics, including age and sex
were not statistically significant association with species. Factors
such as patients received total parenteral nutrition; no of days on
ICU and number of days on mechanical ventilation prior to blood
culture were independently related to infection by C. albicans
(p = 0.030, p = 0.045, and p = 0.035, respectively). The
average number of days on ICU or ventilation BPS for different
Candida spp. is displayed in Figure 3. Though other variables
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TABLE 3 | Clinical and Laboratory Standards Institute antifungal sensitivities of Candida spp.
Species (no. tested) Agent MIC (mg/L)
Range MIC50∗ MIC90∗∗ No. I (%) No. R (%)
C. albicans (n = 86) AMB <0.125–0.5 0.25 0.25
FLY <0.125–0.5 <0.125 <0.125
FLZ <0.125–8 <0.125 0.25 0 0
VOR <0.03–0.06 <0.03 0.06 0 0
ANID <0.015 <0.015 <0.015 0 0
C. glabrata (n = 76) AMB 0.125–0.5 0.25 0.5
FLY <0.125–2 <0.125 <0.125
FLZ <0.125–>64 4 16 75 (94.74) 4(5.26)
VOR <0.03–4 0.06 0.25 0 0
ANID <0.015–0.25 0.03 0.03 0 0
C. parapsilosis (n = 29) AMB 0.125–0.25 0.25 0.25
FLY <0.125 <0.125 <0.125
FLZ <0.125–16 0.5 1 0 0
VOR <0.03 <0.03 <0.03 0 0
ANID 0.03–2 1 1 0 0
C. tropicalis (n = 12) AMB 0.25–0.5 0.5 0.5
FLY <0.125 <0.125 <0.125
FLZ <0.125–0.5 0.25 0.5 0 0
VOR <0.03 <0.03 <0.03 0 0
ANID <0.015–0.06 0.03 0.03 0 0
∗MIC50, Minimum inhibitory concentration for 50% of isolates tested. ∗∗MIC90, Minimum inhibitor concentration for 90% of isolates tested.
have potential impact on infections caused by different Candida
spp. we have not found any statistically significant correlation
in this study. A similar study from Italy showed a significant
relation between solid organ cancer, immunosuppressive therapy,
indwelling urinary catheter and type of fungal isolate from
candidemia patients (Tumbarello et al., 2007). Furthermore,
other risk factors such as neutropenia, glucocorticosteroids,
parenteral nutrition and CVCs were also reported to be associated
with C. albicans and NCAS infections (Dimopoulos et al., 2008).
In this study, out of 134 patient’s record, 129 were found
to be inserted with either central or peripheral CVC. There
was no significant difference in the rate of lines indwelling
between C. albicans and NCAS groups. Within C. albicans
and NCAS groups 18 and 29 patients, respectively, were line
removed after diagnosis. Survival analysis shows a significantly
higher survival of patients infected with C. albicans who
have line removal compared to the non- removal (p < 0.05)
(Figure 4A). Conversely, no significant difference was found
with line removal in NCAS group (p > 0.05) (Figure 4B).
The reason for this may be the high biofilm forming ability
of C. albicans in catheters compared to NCAS such as
C. glabrata. The biofilm phenotype as a significant clinical
entity and this phenotype are highly recalcitrant to antifungal
therapy (Rajendran et al., 2015). This data support the
current guidelines for the management of catheter associated
infection and their clinical management which indicate that
where possible the catheter should be removed in non-
neutropenic patients (Mermel et al., 2009; Cornely et al.,
2012; Koehler et al., 2014). The caveat of this study includes
the complicated nature of the patient population, frequency
of concomitant bacterial infection and prior exposure to
antimicrobials.
Antifungal Sensitivity
A total of 204 clinical isolates were assessed for planktonic
MIC testing of five different antifungal drugs. Concentration
range, MIC50 and MIC90 for each antifungal tested against
different Candida spp. are presented in Table 2. We applied
interpretive breakpoints defined by CLSI for FLZ, VRZ, and
ANID. No resistance was observed for C. albicans, C. tropicalis,
or C. parapsilosis for any antifungal tested. However, the results
showed a considerable prevalence of low azole susceptibility
among C. glabrata isolates, for which was either intermediate
(94.74%) or resistant (5.26%) to FLZ. Currently, no interpretable
breakpoints for amphotericin B (AMB) and flucytosine (FLY)
exist, therefore MIC values and the range of the measured MICs
are given and no statement concerning the clinical resistance
could be made (Table 3). Furthermore, comparing to EUCAST
breakpoints (As of 2013, Arendrup et al., 2013a) we found that
3 (3.95%) of C. glabrata isolates were resistant to anidulafungin
(Table 3). Our susceptibility data are similar to those of other
studies published in recent years, with limited or no resistance
found among C. albicans, C. parapsilosis or C. tropicalis isolates
(Odds et al., 2007). Conversely all isolates of C. glabrata were
considered intermediate for fluconazole except four resistance
based on recent CLSI guidelines (CLSI, 2012). The decreased
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susceptibility of C. glabrata to the azoles is a well-known concern.
Logically, the implications would suggest that patients with
C. glabrata were at the greatest risk, though our data shows
that mortality in C. albicans infection was significantly greater
than C. glabrata infection. This provides further evidence that
the biofilm phenotype as a significant clinical entity and this
phenotype are highly recalcitrant to antifungal therapy (Ramage
et al., 2012). Though we not found any resistance with C. albicans
isolates in their planktonic form, with our expanded knowledge
on biofilm susceptibility to antifungals, the use of these MIC
values to treat biofilm based infections is a matter of concern
(Kuhn et al., 2002; Nett et al., 2011; Rajendran et al., 2015).
In summary, the data herein shows a changing trend in the
prevalence of NCAS causing BSI in Scotland, emphasizing the
need for early and appropriate antifungal treatment for patients
at high risk for candidaemia. In addition, removal of infected
catheter lines, especially with C. albicans, have been shown to
be associated with positive clinical outcome. This suggests the
necessity for the development of rapid diagnosis methods for
catheter related biofilm infections, which in turn as an aid to
improving antifungal therapy.
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